{"id":464,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"},"modified":"2026-10-01T14:53:42","modified_gmt":"2026-10-01T14:53:42","slug":"ensayo-clinico-sobre-el-sindrome-de-barth-con-elamipretida-autorizacion-acelerada-de-la-fda","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/es\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","title":{"rendered":"Elamipretida en el s\u00edndrome de Barth: lo que muestran el ensayo con pacientes 12 y el registro FDA"},"content":{"rendered":"
La elamipretida ahora tiene un producto terminado aprobado por FDA para una indicaci\u00f3n limitada del s\u00edndrome de Barth, pero la aprobaci\u00f3n se basa en un conjunto de datos inusual de enfermedades raras. La porci\u00f3n aleatoria incluy\u00f3 a participantes de 12 y no cumpli\u00f3 con sus dos criterios de valoraci\u00f3n principales.<\/p>
Lo que muestra el registro<\/h2>
Todos los participantes asignados al azar a 12 eran hombres, con edades de 12 a 35 a\u00f1os, en un sitio de US.<\/li>
El ensayo aleatorizado no mostr\u00f3 superioridad en sus criterios de valoraci\u00f3n principales 6: caminata de minutos o fatiga.<\/li>
FDA otorg\u00f3 la aprobaci\u00f3n acelerada bas\u00e1ndose en la fuerza del extensor de la rodilla observada durante un seguimiento abierto m\u00e1s prolongado y requiri\u00f3 un ensayo confirmatorio.<\/li><\/ul><\/div><\/div>Ilustraci\u00f3n editorial original del contexto de la investigaci\u00f3n. No es una figura de estudio, una imagen de un paciente, una fotograf\u00eda del producto suministrado ni una representaci\u00f3n de material de prueba.<\/figcaption><\/figure>
Registro de estudio<\/h2>
El estudio cruzado compar\u00f3 per\u00edodos de semanas 12 de elamipretida y placebo, separados por lavado. Diez participantes ingresaron a la extensi\u00f3n de etiqueta abierta y ocho fueron seguidos durante la semana 168.<\/p>
Poblaci\u00f3n aleatoria<\/strong>12 pacientes con s\u00edndrome de Barth gen\u00e9ticamente confirmado<\/span><\/div>
Criterios de valoraci\u00f3n principales<\/strong>Distancia caminada en minutos 6 y puntuaci\u00f3n de fatiga total<\/span><\/div>
Resultado primario<\/strong>Ninguno de los criterios de valoraci\u00f3n se cumpli\u00f3 en la parte cruzada aleatoria<\/span><\/div>
Fecha de aprobaci\u00f3n<\/strong>Septiembre 19, 2025<\/span><\/div>
Tipo de aprobaci\u00f3n<\/strong>Acelerado; Se requiere prueba confirmatoria.<\/span><\/div><\/div><\/div>
Resultados en contexto<\/h2>
FDA informa una fuerza basal media del extensor de rodilla de Newtons 124. Los cambios medianos en la semana 12 fueron \u22125 newtons con placebo y +4 con elamipretida; Durante la extensi\u00f3n de etiqueta abierta aparecieron cambios descriptivos m\u00e1s importantes, incluidos + 63 newtons entre ocho participantes en la semana 168.<\/p>
El cambio de etiqueta abierta es vulnerable a los efectos del tiempo, las expectativas, la continuaci\u00f3n selectiva y la ausencia de un control concurrente. Por lo tanto, FDA requiri\u00f3 confirmaci\u00f3n posterior a la aprobaci\u00f3n de que el cambio de concentraci\u00f3n se traduce en un beneficio para el paciente.<\/p>
Lo que este estudio no puede responder<\/h2>
El conjunto de datos es extremadamente peque\u00f1o y no puede soportar el an\u00e1lisis de subgrupos.<\/p>
La aprobaci\u00f3n se aplica a Forzinity para pacientes con s\u00edndrome de Barth que pesen al menos 30 kg, no a materiales gen\u00e9ricos \u201cSS-31\u201d ni a otros usos.<\/p>","protected":false},"excerpt":{"rendered":"
La elamipretida ahora tiene un producto terminado aprobado por FDA para una indicaci\u00f3n limitada del s\u00edndrome de Barth, pero la aprobaci\u00f3n se basa en un conjunto de datos inusual de enfermedades raras. La porci\u00f3n aleatoria incluy\u00f3 a participantes de 12 y no cumpli\u00f3 con sus dos criterios de valoraci\u00f3n principales.<\/p>","protected":false},"author":1,"featured_media":2780,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"364","pim_article_type":"Published study case","pim_evidence_level":"Small randomized crossover trial plus FDA accelerated-approval record","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"FDA Drug Trials Snapshot: Forzinity\",\"url\":\"https:\/\/www.fda.gov\/drugs\/drug-trials-snapshots\/drug-trials-snapshots-forzinity\",\"note\":\"Trial population, endpoint results and approval basis.\"},{\"title\":\"Elamipretide phase 2\/3 Barth syndrome crossover trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33077895\/\",\"note\":\"Primary published trial; PMID 33077895.\"},{\"title\":\"FDA accelerated approval announcement for Forzinity\",\"url\":\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-treatment-barth-syndrome\",\"note\":\"Approval scope and confirmatory requirement.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-464","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"\n
Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show - NHD<\/title>\n<meta name=\"description\" content=\"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/es\/ensayo-clinico-sobre-el-sindrome-de-barth-con-elamipretida-autorizacion-acelerada-de-la-fda\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show\" \/>\n<meta property=\"og:description\" content=\"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/es\/ensayo-clinico-sobre-el-sindrome-de-barth-con-elamipretida-autorizacion-acelerada-de-la-fda\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-01T14:53:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-10-01T14:53:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\"},\"wordCount\":284,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/elamipretide.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\",\"name\":\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/elamipretide.webp\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-10-01T14:53:42+00:00\",\"description\":\"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/elamipretide.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/elamipretide.webp\",\"width\":1536,\"height\":1024,\"caption\":\"AI-generated editorial illustration.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/es\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Elamipretida en el s\u00edndrome de Barth: lo que muestran el ensayo con pacientes 12 y el registro FDA - NHD","description":"La elamipretida ahora tiene un producto terminado aprobado por FDA para una indicaci\u00f3n limitada del s\u00edndrome de Barth, pero la aprobaci\u00f3n se basa en un conjunto de datos inusual de enfermedades raras. E\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/es\/ensayo-clinico-sobre-el-sindrome-de-barth-con-elamipretida-autorizacion-acelerada-de-la-fda\/","og_locale":"es_ES","og_type":"article","og_title":"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show","og_description":"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026","og_url":"https:\/\/nhdbio.com\/es\/ensayo-clinico-sobre-el-sindrome-de-barth-con-elamipretida-autorizacion-acelerada-de-la-fda\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-10-01T14:53:42+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-10-01T14:53:42+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"},"wordCount":284,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/elamipretide.webp","articleSection":["Published Study Reviews"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","url":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","name":"Elamipretida en el s\u00edndrome de Barth: lo que muestran el ensayo con pacientes 12 y el registro FDA - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/elamipretide.webp","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-10-01T14:53:42+00:00","description":"La elamipretida ahora tiene un producto terminado aprobado por FDA para una indicaci\u00f3n limitada del s\u00edndrome de Barth, pero la aprobaci\u00f3n se basa en un conjunto de datos inusual de enfermedades raras. E\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/elamipretide.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/elamipretide.webp","width":1536,"height":1024,"caption":"AI-generated editorial illustration."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Materias primas pept\u00eddicas y s\u00edntesis personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipo t\u00e9cnico de NHD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"El equipo t\u00e9cnico de NHD mantiene documentaci\u00f3n del cat\u00e1logo de uso de investigaci\u00f3n y res\u00famenes de evidencia. Los art\u00edculos revisados \u200b\u200benlazan con art\u00edculos revisados \u200b\u200bpor pares, registros de ensayos y registros regulatorios, conservan hallazgos nulos y limitaciones de estudios, y distinguen las intervenciones publicadas de los materiales del cat\u00e1logo. Se puede utilizar dibujo asistido por AI para la estructura; los enlaces de fuentes y los l\u00edmites de las pruebas permanecen visibles. Este trabajo no es una revisi\u00f3n por pares independiente ni un consejo m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/es\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/comments?post=464"}],"version-history":[{"count":2,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/464\/revisions"}],"predecessor-version":[{"id":2818,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/464\/revisions\/2818"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media\/2780"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media?parent=464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/categories?post=464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/tags?post=464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Cient\u00edfico](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828.png\")